CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions

CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.

CareDx in the News

CareDx Launches Olerup QTYPE® at ASHISeptember 28, 2016
CareDx Announces Closing of Public Offering of Common StockSeptember 26, 2016
CareDx Announces Pricing of Public Offering of Common StockSeptember 21, 2016
CareDx Announces Proposed Public Offering of Common StockSeptember 21, 2016
CareDx Reports Status of Form 10-QAugust 16, 2016
CareDx Reports Preliminary Second Quarter 2016 Financial ResultsAugust 10, 2016
CareDx Presents Validation of AlloSure® at AACC Conference SessionAugust 4, 2016
CareDx to Announce Q2 EarningsAugust 1, 2016
CareDx Supports FDA Development of NGS GuidelinesAugust 1, 2016
CareDx Appoints Douglas Miller to Its Board of DirectorsJuly 15, 2016
First Coast's Proposed Cut in Reimbursement Rate of Blood Test Threatens Heart Transplant Patient Care in FloridaJuly 13, 2016
Novitas's Proposed Cut in Reimbursement Rate of Blood Test Threatens Heart Transplant Patient Care in TexasJuly 13, 2016
Press Release Archive

Information on CareDx

CareDx at ISHLT 2016
CareDx Company Update
Information on the CareDx Public offer to the shareholders of Allenex

Learn about AlloMap


AlloMap is a non-invasive blood test that helps physicians identify the risk of acute cellular rejection in heart transplant recipients.

Upcoming Events

Look for CareDx at the following 2016 conferences.
American Society for Histocompatibility and Immunogenetics
St. Louis, MO
September 26-30, 2016
American Society of Nephrology – Kidney Week
Chicago, IL
November 15-20, 2016

I confirm that I am not in the following jurisdictions:

Australia, Hong Kong, Japan, Canada, New Zealand or South Africa and am able to receive the following report and documents.